TriLink and Quantoom Ink License and Supply Agreement for mRNA Capping Technology
TriLink’s CleanCap capping technology, to which Quantoom will have access in the new partnership, has been used in the majority of all approved COVID-19 mRNA and saRNA vaccines.
robot arm moving plastic bottle to conveyor belt of auto capping and labeling machine at cosmetic and skin care manufacturing. cosmetic industry and ai technology machinery concept. | Image Credit: © gumpapa - stock.adobe.com
TriLink Biotechnologies, a San Diego-headquartered company that is part of Maravai LifeSciences, has signed a non-exclusive license and supply agreement with Belgium-based Quantoom Biosciences, under the terms of which Quantoom will gain access to TriLink’s messenger RNA (mRNA) capping technology, known as CleanCap (1).
Since debuting in 2017, the CleanCap technology has been used in the majority of all approved COVID-19 mRNA and self-amplifying RNA (saRNA) vaccines, according to a TriLink press release on June 3, 2025 (1). It will now be integrated into Quantoom’s Ntensify (sa)mRNA production platform, which the two companies said will help to accelerate the RNA production process.
"Strengthening global health against infectious diseases requires strong industry partnerships," Becky Buzzeo, Maravai chief commercial officer, said in the release (1). "We're excited for the Quantoom production platform to incorporate TriLink’s CleanCap reagents, a proven mRNA capping technology to deliver essential therapeutics and vaccines to nations with limited resources."
“We are committed to making the RNA technology more accessible and scalable, and this partnership with TriLink is a key step toward that goal," said José Castillo, CEO of Quantoom Biosciences, in the release (1). "By integrating CleanCap analogs into our platform, we can further empower researchers and manufacturers to develop life-saving vaccines and therapeutics for communities in need."
How the technology works
According to TriLink, the CleanCap technology produces optimal 5’ cap structures that demonstrate efficiency of over 95% (1). This co-transcriptional capping solution, the company said, improves both mRNA yield and process time dramatically, compared to legacy capping methods.
Combining the capping technology with Quantoom’s production platform will be a benefit to customers because it will allow for the development of unique (sa)mRNA drugs through clinical development phases, according to the press release (1).
Other partnerships for Quantoom
In another collaboration, Quantoom Biosciences announced in March 2025 that it would be partnering with TechInvention Lifecare Pvt. Ltd. for the accessibility, scalability, and affordability of RNA-based vaccines, with a memorandum of understanding being signed during the Belgian Economic Mission to India (2). TechInvention will use Quantoom’s RNA N-Force toolbox to de-risk and accelerate the development of RNA-based vaccines from sequence design with Quantoom’s Ncode, RNA production with its Ntensify product, and encapsulation with the lipid-like delivery chemistry in bulk with Ncapsulate (3).
Furthermore, TechInvention will be using Quantoom’s translation research and regulatory expertise and its good manufacturing practice (GMP) manufacturing capabilities to develop and commercialize novel RNA-based products (3). TechInvention plans to be GMP-ready at Ntensify midi scale by the end of 2025.
References
1. TriLink Biotechnologies. TriLink BioTechnologies and Quantoom Biosciences Sign License and Supply Agreement for CleanCap mRNA Capping Technology. Press Release. June 3, 2025.
2. Quantoom. India and Belgium Unite to Advance RNA-Based Vaccines: MoU Signed Between Techinvention and Quantoom Biosciences, in the presence of Her Royal Highness Princess Astrid of Belgium during the Belgian Economic Mission to India. Press Release. March 5, 2025.
3. Haigney, S. TechInvention and Quantoom Biosciences Collaborate on RNA-Based Vaccines. BioPharmInternational.com, March 5, 2025.
